Accumulation of various mediators in sera and SWEs collected from healthy subjects and patients with RA
. | Sera, mean ± SEM . | . | SWEs, mean ± SEM . | . | ||
|---|---|---|---|---|---|---|
. | Healthy subjects . | patients with RA . | Healthy subjects . | patients with RA . | ||
| BlyS, pg/mL | 2811 ± 140 | 4550 ± 300* | 5686 ± 275 | 8758 ± 600* | ||
| BlyS net increase, pg/ML | — | — | 2822 ± 180 | 4200 ± 400 | ||
| G-CSF, pg/mL | < 15 | < 15 | 1988 ± 507 | 1895 ± 391 | ||
| CXCL8, pg/mL | < 15 | < 15 | 914 ± 191 | 6789 ± 1464† | ||
| TNF-α, pg/mL | ND | ND | 174 ± 67 | 100 ± 77 | ||
| C5a, ng/mL | 8.1 ± 1.3 | 25 ± 5‡ | 12 ± 1.4 | 39 ± 4.7* | ||
| IL-1ra, ng/mL | 0.18 ± 0.5 | 0.12 ± 0.4 | 41 ± 3 | 47 ± 8 | ||
. | Sera, mean ± SEM . | . | SWEs, mean ± SEM . | . | ||
|---|---|---|---|---|---|---|
. | Healthy subjects . | patients with RA . | Healthy subjects . | patients with RA . | ||
| BlyS, pg/mL | 2811 ± 140 | 4550 ± 300* | 5686 ± 275 | 8758 ± 600* | ||
| BlyS net increase, pg/ML | — | — | 2822 ± 180 | 4200 ± 400 | ||
| G-CSF, pg/mL | < 15 | < 15 | 1988 ± 507 | 1895 ± 391 | ||
| CXCL8, pg/mL | < 15 | < 15 | 914 ± 191 | 6789 ± 1464† | ||
| TNF-α, pg/mL | ND | ND | 174 ± 67 | 100 ± 77 | ||
| C5a, ng/mL | 8.1 ± 1.3 | 25 ± 5‡ | 12 ± 1.4 | 39 ± 4.7* | ||
| IL-1ra, ng/mL | 0.18 ± 0.5 | 0.12 ± 0.4 | 41 ± 3 | 47 ± 8 | ||
Values are mean ± SEM of BLyS, G-CSF, CXCL8, TNF, C5a, and IL-1ra levels in sera and SWEs from patients with RA and healthy subjects. The net increase of SWE BLyS is also reported, as calculated by subtracting, for each sample, the amount of BLyS present in the serum from the total amount of BLyS recovered in the corresponding autologous SWE.
ND indicates not done.
Symbols indicate significant differences between patients with RA and healthy subjects: *P < .0001; †P < .001; ‡P < .05.